Expression of HTLV-1 in Transgenic Mice
Transgenic technology has been used to determine the biological effects of individual viral gene products in an intact organism. This approach may minimize much of the pathogenic complexity seen during natural infection of animals as a result of variable targeting, differential expression of antigens, and the complicating effects of attack by the immune system. Specific transcriptional promoters may be chosen to target gene expression to certain tissues of interest or to broaden the repertoire of tissue-specific expression beyond what is commonly seen in natural infections. This technology may also be used to derive models of human disease and to create useful cellular and biochemical reagents for the investigation of viral pathogenesis.
KeywordsLeukemia Neurol Peri Nism Rosen
Unable to display preview. Download preview PDF.
- 7.Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet ii: 1032Google Scholar
- 20.Nerenberg Ml, Wiley CA (1988) The HTLV-1 tat protein induces tissue specific disorders of neoplasia and atrophy in transgenic mice (manuscript submitted)Google Scholar
- 21.Wiley CA, Nerenberg M, Cros D, Soto-Aguilar MC (1989) HTLV-1 Polymyositis. N Engl J Med (in press)Google Scholar
- 22.Mora CA, Garruto RM, Brown P, Guiroy D, Morgan OS, Rodgers-Johnson P, Ceroni M, Yanagihara R, Goldfarb LG, Gibbs CF Jr, et al (1988) Seroprevalence of antibodies to HTLV-1 in patients with chronic neurological disorders other than tropical spastic paraparesis. Ann Neurol 23: S192–S195CrossRefGoogle Scholar